# Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

> **NCT00319930** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 10 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** CNF1010 (17-AAG)

## Key facts

- **NCT ID:** NCT00319930
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Discontinuation of program
- **Last updated:** 2010-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319930, "Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00319930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*